GlassScriptPhysician profile
Zurab Abayev
NPI 1841283058
$11,275.95
in general payments reported to CMS, 2019-2025
40 companies · $4,291 in 2025
The $4,291 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2021: $778 · 2022: $1,179 · 2023: $1,894 · 2024: $2,957 · 2025: $4,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,108 · Education: $34.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,107.62 |
| Education | $34.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,851.19 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,688.57 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $798.50 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $702.27 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $523.26 | 2023-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $515.51 | 2025 | Rexulti |
| Bard Peripheral Vascular, INC. | $499.83 | 2023-2025 | Lutonix Drug Coated Balloon, Rotarexs 6 F X 135 Cm, Crosser Iq |
| Axsome Therapeutics, INC. | $490.79 | 2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $426.06 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $413.85 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Aimmune Therapeutics, INC. | $361.22 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.08 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $291.57 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $252.52 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $250.16 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $227.12 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mannkind Corporation | $222.92 | 2019-2023 | Afrezza |
| Exact Sciences Corporation | $205.62 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $163.13 | 2024 | Hawkone |
| Lundbeck LLC | $156.36 | 2025 | Vyepti, Rexulti |
| Beone Medicines USA, INC. | $150.00 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $130.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $73.67 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $69.32 | 2019-2025 | |
| Alkermes, INC. | $57.53 | 2024 | Lybalvi |
| Nestle Healthcare Nutrition INC. | $50.73 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.18 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $37.04 | 2025 | Camzyos |
| Insmed, INC. | $36.82 | 2025 | Brinsupri, Arikayce |
| Idorsia Pharmaceuticals US INC | $35.27 | 2022-2023 | Quviviq |
| Horizon Therapeutics Plc | $31.57 | 2022 | |
| Pfizer INC. | $24.25 | 2024 | |
| Viatris Specialty LLC | $24.04 | 2025 | Yupelri |
| Protega Pharmaceutials INC | $23.94 | 2024 | Roxybond |
| Viiv Healthcare Company | $22.86 | 2023 | Dovato |
| Ars Pharmaceuticals Operations, INC. | $21.41 | 2025 | Neffy |
| Astellas Pharma US INC | $21.37 | 2021 | |
| Ardelyx, INC. | $21.23 | 2024 | Ibsrela |
| Ucb, INC. | $19.72 | 2024 | Briviact |
| Kowa Pharmaceuticals America, INC. | $16.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zurab Abayev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.